SCHEDULE: Vanguard Discloses 5.97% Stake in Recursion Pharmaceuticals

Vanguard Portfolio Management has reported beneficial ownership of 5.97% of Recursion Pharmaceuticals Inc. common stock as of June 30, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, now beneficially owns 31,369,274 shares of Recursion Pharmaceuticals Inc. common stock.
• This holding represents 5.97% of the total class of securities.
• The filing indicates that Vanguard Portfolio Management has sole dispositive power over 31,369,274 shares and sole voting power over 237,675 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, indicating significant institutional confidence from Vanguard, but without direct company performance updates.

Positives

• Significant institutional ownership by a major asset manager like Vanguard can provide stability and confidence to the market.
• Vanguard's investment suggests a positive long-term outlook on Recursion Pharmaceuticals' business model and growth potential.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Recursion Pharmaceuticals. It is a disclosure of ownership by Vanguard.

Industry Context

StockSavvy.ai notes that significant institutional filings like this Schedule 13G from a major player like Vanguard often signal increased investor interest or a strategic shift in holdings within the biotechnology and pharmaceutical sectors, particularly for companies focused on AI-driven drug discovery like Recursion Pharmaceuticals.

Stakeholder Impact

• Shareholders may see increased stability in the stock price due to Vanguard's substantial and potentially long-term investment.
• The increased institutional ownership could attract further investor attention to Recursion Pharmaceuticals.

Next Steps

• Monitor future filings from Vanguard for any changes in ownership.
• Observe Recursion Pharmaceuticals' subsequent financial reports and strategic announcements for performance indicators.

Key Dates

Recommendation

This filing is an ownership disclosure by a major institutional investor, not a performance report from Recursion Pharmaceuticals. While Vanguard's investment is a positive signal of confidence, it does not provide sufficient information to warrant a buy or sell recommendation on its own. A 'hold' recommendation is appropriate pending further company-specific performance data.

Keywords

Vanguard, Recursion Pharmaceuticals, Schedule 13G, Institutional Ownership, Beneficial Ownership, Common Stock, Investment Management, SEC Filing